Business Context and Reporting Period
Company: Synthetic Blood International, Inc. (Note: Metadata referenced "Tenax Therapeutics," but the filing text identifies the registrant as Synthetic Blood International, Inc.)
Reporting Period: Quarterly period ended July 31, 1999.
Status: Development Stage Company. The firm is in the pre-clinical trial stage of product development and has no commercial revenue. It faces a "Going Concern" warning due to accumulated losses and a working capital deficit.
Key Financial Metrics
| Metric | Three Months Ended July 31, 1999 | Three Months Ended July 31, 1998 |
|---|---|---|
| Revenue | $0 | $0 |
| Net Loss | $(220,357) | $(227,662) |
| Accumulated Deficit | $(10,622,357) | $(10,401,999) |
| Cash and Cash Equivalents (Ending) | $90,788 | $455,785 |
| Working Capital Deficit | $(420,760) | Not explicitly stated |
| Total Current Liabilities | $541,933 | Not explicitly stated |
| Notes Payable (Current + Long-term) | $106,890 | Not explicitly stated |
Cash Flow Summary (Three Months Ended July 31, 1999):
- Net cash used in operating activities: $(7,370,342)
- Net cash used in investing activities: $(722,993)
- Net cash provided by financing activities: $8,184,123 (primarily from stock sales and notes payable).
Material Changes vs. Prior Period
- Expenses: Total expenses decreased by approximately $14,000 compared to the prior year quarter. Research and Development (R&D) expenses increased slightly to $43,698 (from $35,107) due to higher contract wages. General and Administrative (G&A) expenses decreased to $172,508 (from $193,263) due to lower professional fees, wages, and travel, partially offset by a $13,000 increase in rent for a new California laboratory and a $14,000 one-time moving expense.
- Liquidity: Cash balances declined significantly from $193,013 at April 30, 1999, to $90,788 at July 31, 1999, despite significant financing inflows during the quarter.
- Capital Structure: The company issued significant common stock and options during the quarter to raise capital, increasing outstanding shares from 55,314,324 to 57,059,078.
Outlook, Risks, and Management Commentary
- Going Concern: Management states that the company's continuation is dependent on generating sufficient cash flow, meeting obligations, and obtaining additional financing. There is substantial doubt about the company's ability to continue as a going concern without further funding.
- Funding Needs: Significant additional financing is required to complete pre-clinical testing and proceed to Phase I, II, and III human clinical trials. No firm commitments for additional capital existed as of July 31, 1999.
- Regulatory Risk: There is no assurance that FDA approval will be granted for the company's products once applied for.
- Year 2000 Compliance: The company's internal Y2K program was substantially complete. The primary risk identified is potential delays in clinical trials or R&D due to infrastructure failures or non-compliance by third-party suppliers.
- Market Risk: The company has no exposure to foreign currency exchange rates or interest rate risk and holds no derivative financial instruments.
Investor Verification Checklist
- Verify the company's ability to secure the "significant additional financing" required to reach Phase I clinical trials.
- Confirm the status of the new California research laboratory and associated lease obligations.
- Assess the timeline and probability of FDA approval for the pre-clinical products.
- Review the terms of the $106,890 in notes payable and the $284,208 in accounts payable to understand immediate liquidity pressures.
- Monitor the dilution impact of recent stock issuances and outstanding options granted to investors.